Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial (NCT05337033) | Clinical Trial Compass
RecruitingPhase 2
Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial
Canada20 participantsStarted 2024-10-11
Plain-language summary
Chronic headaches are a major cause of disability among adolescents. Cannabis products have supported the management of headaches in adults and may play a role in pediatric chronic pain. We propose a multisite, open-label, tolerability study conducted across three centers in Canada of Cannabidiol-enriched Cannabis Herbal Extract in adolescents (ages 14 to 17 years old) with chronic headaches. The study includes a one month baseline assessment, four months of escalating treatment doses and a weaning period. Our primary outcome is tolerability defined as the number and severity of reported adverse events.
Who can participate
Age range14 Years – 17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adolescents aged between 14-17 years of age at the time of screening.
✓. Diagnosed with Chronic Migraine according to ICHD-3: headache (migraine-like or tension-type like) occurring on 15 or more days per month for more than 3 months which on at least 8 days per month have features of migraine headache. \[121\]
✓. Failed at least two treatment options on the grounds of safety (tolerability) and/or efficacy, including but not limited to antidepressant (tricyclic antidepressant or selective norepinephrine reuptake inhibitor), magnesium, gabapentinoids topiramate and/or non-pharmacological therapies.
✓. Females who have reached menarche should have a negative pregnancy test during screening.
✓. Must be willing to engage with psychology and physiotherapy throughout the trial as appropriate.
Exclusion criteria
✕. As per the investigator judgement, the participant is not an ideal candidate due to a personal issue or medical condition that is likely to impede in the successful completion of the study
✕. Participants with a history of post-concussion headache or new daily persistent headache
What they're measuring
1
Cannabis-related adverse events
Timeframe: Reported daily through study completion, an average of 6 months
✕. Participants with a diagnosis of medication overuse headache
✕. Participants with cardiac, renal or hepatic disease (assessed by the site investigator)
✕. Participants with complex regional pain syndrome-II
✕. Participants with abnormal ECG findings at baseline (as determined by the investigator)
✕. Participants who are on the following medications: opioids, antipsychotics, antimanic, barbiturates, benzodiazepines, muscle relaxants, sedatives, or tramadol.
✕. Participants with developmental delay or impairments including autism, cerebral palsy or intellectual disability.